Join Swanson Reed, Aston Ryan Malcolm and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.
You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.
On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.
|7:00am – 7:30am:||Session 1: Protecting Intellectual Property (IP)||Joe Seisdedos|
|7:30am – 8:00am:||Session 2: IP & Relevant Tax Considerations||David Coutts|
|8:00am – 8:30am:||Session 3: R&D Tax Incentives||Adam Rogers|
|8:30am – 9:00am:||Session 4: Panel Q&A and Networking Opportunity|
|Joe Seisdedos||David Coutts||Adam Rogers|
|View Joe’s bio||View David’s bio||View Adam’s bio|
Register Before: Friday 13th June
Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.
Contact Amy Nolan for more information:
Ph: 03 9018 5778
Mob: 0435 713 493
Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.
Melbourne-based Imugene Ltd announced in January 2022 the receipt of the company’s FY21 R&D Tax Offset refund of $6,541,921. The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent months, including: Granting of additional patents for the company’s HER-Vaxx Immunotherapy in China and South Korea; Completion of Phase 1a trial of immunotherapy PD1-Vaxx; US Food and Drug Administration (FDA) consent for clinical trials for its oncology treatments. In recent […]
Under SECT 355.405 ITAA97, an entity cannot claim R&D expenditure in situations where: (a) when an entity incurs R&D expenditure, consideration has been received, or was reasonably expected to be received: o as a direct or indirect result of the expenditure being incurred; and o regardless of the results of the activities on which the expenditure is incurred; and (b) that consideration is equal to or greater than the expenditure. The spirit of this provision is to ensure companies only […]